Literature DB >> 27591954

Brucella abortus ΔrpoE1 confers protective immunity against wild type challenge in a mouse model of brucellosis.

Jonathan W Willett1,2, Julien Herrou1,2, Daniel M Czyz1,2, Jason X Cheng3, Sean Crosson1,2,4.   

Abstract

The Brucella abortus general stress response (GSR) system regulates activity of the alternative sigma factor, σ(E1), which controls transcription of approximately 100 genes and is required for persistence in a BALB/c mouse chronic infection model. We evaluated the host response to infection by a B. abortus strain lacking σ(E1) (ΔrpoE1), and identified pathological and immunological features that distinguish ΔrpoE1-infected mice from wild-type (WT), and that correspond with clearance of ΔrpoE1 from the host. ΔrpoE1 infection was indistinguishable from WT in terms of splenic bacterial burden, inflammation and histopathology up to 6weeks post-infection. However, Brucella-specific serum IgG levels in ΔrpoE1-infected mice were 5 times higher than WT by 4weeks post-infection, and remained significantly higher throughout the course of a 12-week infection. Total IgG and Brucella-specific IgG levels peaked strongly in ΔrpoE1-infected mice at 6weeks, which correlated with reduced splenomegaly and bacterial burden relative to WT-infected mice. Given the difference in immune response to infection with wild-type and ΔrpoE1, we tested whether ΔrpoE1 confers protective immunity to wild-type challenge. Mice immunized with ΔrpoE1 completely resisted WT infection and had significantly higher serum titers of Brucella-specific IgG, IgG2a and IFN-γ after WT challenge relative to age-matched naïve mice. We conclude that immunization of BALB/c mice with the B. abortus GSR pathway mutant, ΔrpoE1, elicits an adaptive immune response that confers significant protective immunity against WT infection.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; Brucellosis; General stress response; Vaccine; ecfG; phyR; rpoE1

Mesh:

Substances:

Year:  2016        PMID: 27591954      PMCID: PMC5026968          DOI: 10.1016/j.vaccine.2016.08.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  64 in total

1.  Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway.

Authors:  I Agranovich; D E Scott; D Terle; K Lee; B Golding
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 2.  Brucellosis in sub-Saharan Africa: epidemiology, control and impact.

Authors:  John J McDermott; S M Arimi
Journal:  Vet Microbiol       Date:  2002-12-20       Impact factor: 3.293

3.  An RpoH-like heat shock sigma factor is involved in stress response and virulence in Brucella melitensis 16M.

Authors:  Marie Delory; Régis Hallez; Jean-Jacques Letesson; Xavier De Bolle
Journal:  J Bacteriol       Date:  2006-08-25       Impact factor: 3.490

4.  Complex two-component signaling regulates the general stress response in Alphaproteobacteria.

Authors:  Andreas Kaczmarczyk; Ramon Hochstrasser; Julia A Vorholt; Anne Francez-Charlot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

5.  Dual control of Sinorhizobium meliloti RpoE2 sigma factor activity by two PhyR-type two-component response regulators.

Authors:  Bénédicte Bastiat; Laurent Sauviac; Claude Bruand
Journal:  J Bacteriol       Date:  2010-02-12       Impact factor: 3.490

6.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.

Authors:  C M Snapper; W E Paul
Journal:  Science       Date:  1987-05-22       Impact factor: 47.728

7.  Innate immune response in Th1- and Th2-dominant mouse strains.

Authors:  Hiroyuki Watanabe; Kousuke Numata; Takaaki Ito; Katsumasa Takagi; Akihiro Matsukawa
Journal:  Shock       Date:  2004-11       Impact factor: 3.454

Review 8.  Brucella spp. Virulence Factors and Immunity.

Authors:  Mariana X Byndloss; Renee M Tsolis
Journal:  Annu Rev Anim Biosci       Date:  2015-12-23       Impact factor: 8.923

Review 9.  Research progress in live attenuated Brucella vaccine development.

Authors:  Zhen Wang; Qingmin Wu
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

10.  Strong Association Between Human and Animal Brucella Seropositivity in a Linked Study in Kenya, 2012-2013.

Authors:  Eric Mogaka Osoro; Peninah Munyua; Sylvia Omulo; Eric Ogola; Fredrick Ade; Peter Mbatha; Murithi Mbabu; Zipporah Ng'ang'a; Salome Kairu; Marybeth Maritim; Samuel M Thumbi; Austine Bitek; Stella Gaichugi; Carol Rubin; Kariuki Njenga; Marta Guerra
Journal:  Am J Trop Med Hyg       Date:  2015-06-22       Impact factor: 2.345

View more
  5 in total

1.  Molecular control of gene expression by Brucella BaaR, an IclR-type transcriptional repressor.

Authors:  Julien Herrou; Daniel M Czyż; Aretha Fiebig; Jonathan W Willett; Youngchang Kim; Ruiying Wu; Gyorgy Babnigg; Sean Crosson
Journal:  J Biol Chem       Date:  2018-03-22       Impact factor: 5.157

2.  Conserved ABC Transport System Regulated by the General Stress Response Pathways of Alpha- and Gammaproteobacteria.

Authors:  Julien Herrou; Jonathan W Willett; Daniel M Czyż; Gyorgy Babnigg; Youngchang Kim; Sean Crosson
Journal:  J Bacteriol       Date:  2017-02-14       Impact factor: 3.490

3.  Characterization of Brucella abortus mutant strain Δ22915, a potential vaccine candidate.

Authors:  Yanqing Bao; Mingxing Tian; Peng Li; Jiameng Liu; Chan Ding; Shengqing Yu
Journal:  Vet Res       Date:  2017-04-04       Impact factor: 3.683

4.  Next-Generation High-Throughput Functional Annotation of Microbial Genomes.

Authors:  Ralph S Baric; Sean Crosson; Blossom Damania; Samuel I Miller; Eric J Rubin
Journal:  mBio       Date:  2016-10-04       Impact factor: 7.867

Review 5.  Persistence of Intracellular Bacterial Pathogens-With a Focus on the Metabolic Perspective.

Authors:  Wolfgang Eisenreich; Thomas Rudel; Jürgen Heesemann; Werner Goebel
Journal:  Front Cell Infect Microbiol       Date:  2021-01-14       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.